Episode 1: Advancing Patient Care in Non–Muscle-Invasive Bladder Cancer

A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in patient care while highlighting recent treatment advances that offer promising solutions.

Now Viewing

EP: 1.Episode 1: Advancing Patient Care in Non–Muscle-Invasive Bladder Cancer

EP: 2.Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

EP: 3.Episode 2 Video: Identifying Patients With Intermediate Risk in NMIBC

Related Videos

Related Content

Advertisement

February 6th 2025

Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells

Patrick Soon-Shiong, MD

"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up-regulating the suppressive T cells," says Patrick Soon-Shiong, MD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 29th 2025

UTUC roundtable discussions highlight guidelines, patient cases

Urology Times staff

Two recent roundtable discussions focused on the challenges and evolving treatment strategies in upper tract urothelial carcinoma.

January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke

Check out the key regulatory decisions set to happen early this year.

Related Content

Advertisement

February 6th 2025

Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells

Patrick Soon-Shiong, MD

"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up-regulating the suppressive T cells," says Patrick Soon-Shiong, MD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 29th 2025

UTUC roundtable discussions highlight guidelines, patient cases

Urology Times staff

Two recent roundtable discussions focused on the challenges and evolving treatment strategies in upper tract urothelial carcinoma.

January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke

Check out the key regulatory decisions set to happen early this year.